甲状腺结节诊断中基因表达的分层应用
多基因检测灵敏度87.0%、诊断符合率87.9%,均显著高于单基因检测。提出分层应用模式:初次FNA推荐同时基因检测;单基因阴性BSRTCⅢ类结节重复FNA推荐多基因检测。
要点
- 多基因检测灵敏度与诊断符合率均显著优于BRAF V600E单基因检测。
- BSRTCⅢ类结节中多基因检测灵敏度显著高于单基因检测。
- 初次FNA推荐同时基因检测;单基因阴性BSRTCⅢ类重复FNA推荐多基因检测。
核心结论
- 基因检测可作为甲状腺结节良恶性诊断的有效辅助工具,多基因检测诊断性能更优。
- 提出分层应用模式:初次FNA推荐同时基因检测;单基因阴性BSRTCⅢ类结节重复FNA推荐多基因检测。
研究设计与样本
- 术前行FNA和空心针穿刺样本细胞病理检查及基因检测,以术后组织病理为金标准,比较BRAF V600E单基因与多基因检测的诊断性能并结合BSRTC分类分析。
主要发现
- 多基因检测灵敏度87.0%显著高于单基因80.8%(P<0.01),诊断符合率87.9%显著高于82.1%(P<0.01)。
- 多基因检测检出以BRAF V600E突变最常见,其次为CCDC6-RET(E1-E12)融合、ETV6-NTRK3融合和KRAS突变。
- BSRTCⅠ~Ⅴ类结节中,多基因检测灵敏度81.9%显著高于单基因72.8%(P<0.01),野生型恶性风险47.6%低于57.7%(P=0.069)。
- BSRTCⅢ类结节中多基因检测灵敏度86.3%显著高于单基因74.0%(P<0.01);BSRTCⅠ类结节两者灵敏度差异无统计学意义(P>0.05)。
关键数值与推荐
- 多基因检测灵敏度87.0%、诊断符合率87.9%;单基因检测灵敏度80.8%、诊断符合率82.1%。
- BSRTCⅠ~Ⅴ类结节:多基因检测灵敏度81.9%、野生型恶性风险47.6%;单基因检测灵敏度72.8%、野生型恶性风险57.7%(P=0.069)。
- BSRTCⅢ类结节:多基因检测灵敏度86.3%,单基因检测74.0%(P<0.01)。
临床怎么用
- 甲状腺结节FNA时推荐同时进行基因检测以辅助良恶性诊断。
- 初次FNA选择单基因检测且未检出突变的BSRTCⅢ类结节,重复FNA推荐进行多基因检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the value of BRAF V600E and multigene detection and stratified application for the diagnosis of thyroid nodules. Methods: A total of 1 117 patients with thyroid nodules resection at Nanjing Gulou Hospital from December 2020 to July 2022 were enrolled in the study. Fine needle aspiration (FNA) and core biopsy samplings were performed for cytopathologic examination and genetic testings; the findings were combined with BSRTC classification. The diagnostic performance of BRAF V600E and multigene detection were compared. Results: Among the 1, 117 patients who underwent thyroid nodules resection, 285 were male and 832 were female, with a median age of 46 years (range: 24-76 years). Postoperative histopathologic examination confirmed 1 040 cases of thyroid cancer and 77 cases of benign nodules. The sensitivity (87.0% vs. 80.8%, P<0.01) and diagnostic accuracy (87.9% vs. 82.1%, P<0.01) of multigene detection were significantly higher than those of BRAF V600E detection. The result of multigene detection showed that BRAF V600E mutation was the most common finding, followed by CCDC6-RET (E1-E12) fusion, ETV6-NTRK3 fusion, and KRAS mutation. Multigene detection had a higher sensitivity (81.9% vs. 72.8%, P<0.01) and lower cancer risk in wild-type (47.6% vs. 57.7%, P=0.069) than BRAF V600E detection in BSRTCⅠ-Ⅴ lesions. Compared with BRAF V600E detection, multigene had no significant difference of sensitivity in BSRTC Ⅰ lesions, but significantly higher sensitivity (86.3% vs 74.0%, P<0.01) in BSRTC Ⅲ lesions. Conclusions: Genetic detection can be used as an effective tool for the diagnosis of thyroid nodules. A stratified application of molecular markers in the diagnosis of thyroid nodules is proposed. Combined with FNA, single gene or multigene detection both can effectively assist in the diagnosis of thyroid nodules. Moreover, multigene detection is superior to single gene detection. For BSRTC Ⅲ lesion with wild-type BRAF, multigene detection can be considered with a repeated FNA. 目的: 探讨单基因BRAF V600E检测与多基因检测作为甲状腺结节诊断分子标志物的价值及分层应用的模式。 方法: 收集南京大学医学院附属鼓楼医院2020年12月至2022年7月1 117例甲状腺结节切除术患者,均行术前穿刺样本基因检测和细胞病理检查。以术后组织病理结果为“金标准”,比较单基因BRAF V600E检测和多基因检测的诊断性能,并结合甲状腺细胞病理学Bethesda报告系统(BSRTC)分类,分析基因检测在甲状腺结节诊断中的应用模式。 结果: 1 117例甲状腺结节切除术患者,男性285例,女性832例,中位年龄46岁(24~76岁)。经术后组织病理学证实为甲状腺癌1 040例,良性结节77例。多基因检测的灵敏度、诊断符合率显著高于单基因检测(87.0%∶80.8%,P<0.01)、(87.9%∶82.1%,P<0.01)。多基因检测以检出BRAF V600E突变为主,其次是CCDC6-RET(E1-E12)融合突变、ETV6-NTRK3融合突变、KRAS突变。对于BSRTCⅠ~Ⅴ类结节,多基因检测相较于单基因检测具有更高的灵敏度(81.9%∶72.8%,P<0.01)、野生型恶性风险较低(47.6%∶57.7%,P=0.069)。其中,BSRTCⅠ类结节,两者灵敏度其差异无统计学意义(P>0.05);BSRTCⅢ类结节,多基因检测灵敏度更高,差异有统计学意义(86.3%∶74.0%,P<0.01)。 结论: 基因检测可作为甲状腺结节良恶性诊断的有效辅助工具,且多基因的诊断性能更优。本文提出一种优化的基因检测分层应用模式:初次细针穿刺活检,推荐同时进行基因检测;对于初次细针穿刺活检选择单基因但未检测突变的BSRTCⅢ类结节,重复细针穿刺活检推荐进行多基因检测。.
引用
- Guan WY, Zheng JY, Nie L, et al. [Stratified application of gene expression in diagnosis of thyroid nodules]. Zhonghua Bing Li Xue Za Zhi. 2024. PMID: 38433054. doi:10.3760/cma.j.cn112151-20230828-00100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。